-
Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial
(Hinzugefügt: 26.10.2022 um 14:16 Uhr)
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00433-3/fulltext
-
IDSA Guideline on the Treatment and Management of COVID-19 Famotidine
(Hinzugefügt: 08.06.2022 um 10:19 Uhr)
https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/treatment/idsa-covid-19-gl-tx-and-mgmt---famotidine-2022-05-23.pdf
-
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
(Hinzugefügt: 13.05.2022 um 07:57 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00519-0/fulltext
-
In adults hospitalized with COVID-19, adding remdesivir to standard care did not reduce in-hospital mortality
(Hinzugefügt: 13.05.2022 um 07:52 Uhr)
https://www.acpjournals.org/doi/10.7326/J22-0025
-
Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury
(Hinzugefügt: 18.03.2022 um 09:31 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790162
-
Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19
(Hinzugefügt: 14.02.2022 um 16:09 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788857
-
Amantandine
(Hinzugefügt: 14.02.2022 um 14:50 Uhr)
https://notesfrompoland.com/2022/02/12/widely-used-unapproved-drug-not-effective-treating-covid-finds-polish-state-backed-study/
-
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
(Hinzugefügt: 26.08.2021 um 04:15 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00310-6/fulltext
-
Effectiveness of favipiravir in COVID-19: a live systematic review
(Hinzugefügt: 06.08.2021 um 10:53 Uhr)
https://link.springer.com/article/10.1007/s10096-021-04307-1
-
Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial
(Hinzugefügt: 03.08.2021 um 10:16 Uhr)
https://pubmed.ncbi.nlm.nih.gov/33361100/
-
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
(Hinzugefügt: 28.07.2021 um 12:37 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00310-6/fulltext
-
A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19
(Hinzugefügt: 21.07.2021 um 13:15 Uhr)
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00237-6/fulltext
-
Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection
(Hinzugefügt: 20.07.2021 um 10:48 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2782166
-
N-acetylcysteine for the treatment of COVID-19 among hospitalized patients
(Hinzugefügt: 14.07.2021 um 10:00 Uhr)
https://www.sciencedirect.com/science/article/pii/S0163445321003297
-
Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial
(Hinzugefügt: 20.06.2021 um 10:43 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00237-X/fulltext
-
RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19
(Hinzugefügt: 09.06.2021 um 19:33 Uhr)
https://www.recoverytrial.net/news/recovery-trial-finds-aspirin-does-not-improve-survival-for-patients-hospitalised-with-covid-19
-
Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
(Hinzugefügt: 25.04.2021 um 09:46 Uhr)
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00129-2/fulltext
-
Eli Lilly's Arthritis Drug Fails to Prevent Mechanical Ventilation in COVID-19 Patients
(Hinzugefügt: 12.04.2021 um 18:12 Uhr)
https://www.medscape.com/viewarticle/948951
-
Effect of bromhexine in hospitalized patients with COVID-19
(Hinzugefügt: 22.03.2021 um 07:30 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970656/
-
Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia
(Hinzugefügt: 12.03.2021 um 06:16 Uhr)
https://www.roche.com/investors/updates/inv-update-2021-03-11.htm
-
The REMDACTA clinical trial of Actemra/RoActemra plus Veklury did not meet its primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia or its key secondary endpoints compared to Veklury alone
(Hinzugefügt: 11.03.2021 um 09:06 Uhr)
https://www.roche.com/de/media/releases/med-cor-2021-03-11.htm
-
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
(Hinzugefügt: 05.03.2021 um 06:48 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00461-X/fulltext
-
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
(Hinzugefügt: 05.03.2021 um 06:45 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00099-0/fulltext
-
Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis
(Hinzugefügt: 24.02.2021 um 08:47 Uhr)
https://jamanetwork.com/journals/jama/article-abstract/2776688
-
Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors
(Hinzugefügt: 12.02.2021 um 08:30 Uhr)
https://www.pnas.org/content/118/8/e2024420118
-
Interferon
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1
-
Wenig Evidenz für Tocilizumab
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.aerzteblatt.de/nachrichten/117643/COVID-19-Wenig-Evidenz-fuer-Tocilizumab-in-randomisierten-Studien-trotz-positiver-Erfahrungsberichte
-
Tocilizumab
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2028836
-
Tocilizumab
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.nature.com/articles/d41586-020-02972-4
-
Oseltamivir
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.sciencedirect.com/science/article/pii/S0042682220301720
-
Lopinavir/ Ritonavir
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1
-
Interferon
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.sciencemag.org/news/2020/10/remdesivir-and-interferon-fall-flat-who-s-megastudy-covid-19-treatments